Additionally, an increase in cell death was observed following the treatment of MDA-MB-231 cells with anti-DR5 mAb-conjugated SLN of gamma-secretase inhibitor, which aligns with higher tumor regression in a breast cancer mouse model compared to non-targeted SLN or the free drug given intravenously (10 mg/kg) twice a week for four weeks [40]. This evidence concerns the gene TNFRSF10B and neoplasm.